ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
74citing papers in PubMed, 1 pooled it
5.7field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 1 synthesis or guideline pooled it, 117 citations in OpenAlex.
- The efficacy of chimeric antigen receptor (CAR) immunotherapy in animal models for solid tumors: A systematic review and meta-analysis.PloS one · 2017Pooled it
- Rewiring immunity with in vivo CAR T cell engineering.Nature cancer · 2026Review
- The TCR in CAR T cell therapy: use it or lose it?Cancer gene therapy · 2026Review
- Engagement of the TCR against an oncolytic virus generates a population of effector CAR T cells with potent antitumor activity.Science advances · 2026Article
- Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies.Molecular cancer · 2026Review
- Innovative combinatory approaches with dendritic cell-based vaccines: bridging preclinical insights and clinical challenges.Clinical and experimental medicine · 2026Review
- Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy.Frontiers in immunology · 2026Review
- Reprogramming adoptive cell therapy for osteosarcoma: engineering, vaccination, and tumor microenvironment remodeling.Frontiers in immunology · 2026Review
- Emerging frontiers in adoptive cell therapies: innovations, challenges, and future perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.Cancer cell international · 2025Review
- Antigen-specific T cell immunotherapy by in vivo mRNA delivery.bioRxiv : the preprint server for biology · 2024Article
- Enhancing Dendritic Cell Cancer Vaccination: The Synergy of Immune Checkpoint Inhibitors in Combined Therapies.International journal of molecular sciences · 2024Review
- Car T Cells in Solid Tumors: Overcoming Obstacles.International journal of molecular sciences · 2024Review
- Lymph Node-Targeted Vaccine Boosting of TCR T-cell Therapy Enhances Antitumor Function and Eradicates Solid Tumors.Cancer immunology research · 2024Article
- Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.International journal of molecular sciences · 2024Review
- CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.Nature reviews. Clinical oncology · 2024Review
- CAR-based immunotherapy for breast cancer: peculiarities, ongoing investigations, and future strategies.Frontiers in immunology · 2024Review
- Ex-vivo CS1-OKT3 dual specific bivalent antibody-armed effector T cells mediate cellular immunity against multiple myeloma.Scientific reports · 2023Article
- Simultaneous evaluation of treatment efficacy and toxicity for bispecific T-cell engager therapeutics in a humanized mouse model.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2023Article
- Dual TCR-Expressing T Cells in Cancer: How Single-Cell Technologies Enable New Investigation.ImmunoHorizons · 2023Article
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 2 institutions in 1 country.
Clare Y SlaneyCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. michael.kershaw@petermac.org clare.slaney@petermac.org.
Bianca von ScheidtCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Alexander J DavenportCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Jennifer A WestwoodCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Sherly MardianaCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
David C TscharkeJohn Curtin School of Medical Research, Australian National University, Canberra, Australia.
Sarah EllisCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
H Miles PrinceCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Joseph A TrapaniCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Ricky W JohnstoneCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Mark J SmythImmunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Michele W TengCancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Aesha AliCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Zhiya YuCenter for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland.
Steven A RosenbergCenter for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland.
Nicholas P RestifoCenter for Cancer Research, National Cancer Institute, National Institute of Health, Bethesda, Maryland.
Paul NeesonCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Phillip K DarcyCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia.
Michael H KershawCancer Immunology Program, Peter MacCallum Cancer Center, Melbourne, Victoria, Australia. michael.kershaw@petermac.org clare.slaney@petermac.org.
Peter MacCallum Cancer Centre · AUAustralian National University · AU
Funding
Adoptive Cell Transfer Immunotherapy of CancerZIABC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2025
$56.8MBuilding on the success of the adoptive immunotherapy of cancerZIABC010763 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2009 to 2020
$25.0MAdoptive Cell Transfer Immunotherapy of CancerZ01BC010984 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ROSENBERG, STEVEN · 2008 to 2008
$1.5MIntramural NIH HHS Z01 BC010984
Abstract
PubMed holds no abstract for this paper.
Indexed as
Immunotherapy, AdoptiveAnimalsAutoantigensBrain NeoplasmsBreast NeoplasmsCancer VaccinesCD8-Positive T-LymphocytesCell Line, TumorCell ProliferationErb-b2 Receptor Tyrosine KinasesFemaleFlow Cytometrygp100 Melanoma AntigenHumansInterferon-gammaMiceAutoantigensCancer VaccinesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesgp100 Melanoma AntigenInterferon-gammaReceptors, Antigen, T-Cell
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.